Literature DB >> 31820222

Molecular modeling of a series of dehydroquinate dehydratase type II inhibitors of Mycobacterium tuberculosis and design of new binders.

Paulo H de S Miranda1, Estela M G Lourenço1, Alexander M S Morais1, Pedro I C de Oliveira2, Priscilla S de S N Silverio2, Alessandro K Jordão1, Euzébio G Barbosa3,4.   

Abstract

Tuberculosis, caused by Mycobacterium tuberculosis (M. tuberculosis), is still responsible for a large number of fatal cases, especially in developing countries with alarming rates of incidence and prevalence worldwide. Mycobacterium tuberculosis has a remarkable ability to develop new resistance mechanisms to the conventional antimicrobials treatment. Because of this, there is an urgent need for novel bioactive compounds for its treatment. The dehydroquinate dehydratase II (DHQase II) is considered a key enzyme of shikimate pathway, and it can be used as a promising target for the design of new bioactive compounds with antibacterial action. The aim of this work was the construction of QSAR models to aid the design of new potential DHQase II inhibitors. For that purpose, various molecular modeling approaches, such as activity cliff, QSAR models and computer-aided ligand design were utilized. A predictive in silico 4D-QSAR model was built using a database comprising 86 inhibitors of DHQase II, and the model was used to predict the activity of the designed ligands. The obtained model proved to predict well the DHQase II inhibition for an external validation dataset ([Formula: see text] = 0.72). Also, the Activity Cliff analysis shed light on important structural features applied to the ligand design.

Entities:  

Keywords:  Activity cliff; DHQase II; Drug design; QSAR; Shikimate; Tuberculosis

Year:  2019        PMID: 31820222     DOI: 10.1007/s11030-019-10020-1

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  44 in total

1.  A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.

Authors:  Alexander L Perryman; Weixuan Yu; Xin Wang; Sean Ekins; Stefano Forli; Shao-Gang Li; Joel S Freundlich; Peter J Tonge; Arthur J Olson
Journal:  J Chem Inf Model       Date:  2015-02-17       Impact factor: 4.956

Review 2.  Engineering the shikimate pathway for biosynthesis of molecules with pharmaceutical activities in E. coli.

Authors:  Ming Jiang; Haoran Zhang
Journal:  Curr Opin Biotechnol       Date:  2016-02-24       Impact factor: 9.740

Review 3.  Exploring the Untapped Biosynthetic Potential of Apicomplexan Parasites.

Authors:  Jack G Ganley; Maria Toro-Moreno; Emily R Derbyshire
Journal:  Biochemistry       Date:  2017-10-18       Impact factor: 3.162

4.  Applications of Ensemble Docking in Potential Inhibitor Screening for Mycobacterium tuberculosis Isocitrate Lyase Using a Local Plant Database.

Authors:  Yie-Vern Lee; Sy Bing Choi; Habibah A Wahab; Theam Soon Lim; Yee Siew Choong
Journal:  J Chem Inf Model       Date:  2019-03-14       Impact factor: 4.956

5.  In silico comparison of antimycobacterial natural products with known antituberculosis drugs.

Authors:  Marlene Espinoza-Moraga; Nicholas M Njuguna; Grace Mugumbate; Julio Caballero; Kelly Chibale
Journal:  J Chem Inf Model       Date:  2013-02-22       Impact factor: 4.956

6.  Structural investigation of inhibitor designs targeting 3-dehydroquinate dehydratase from the shikimate pathway of Mycobacterium tuberculosis.

Authors:  Marcio V B Dias; William C Snee; Karen M Bromfield; Richard J Payne; Satheesh K Palaninathan; Alessio Ciulli; Nigel I Howard; Chris Abell; James C Sacchettini; Tom L Blundell
Journal:  Biochem J       Date:  2011-06-15       Impact factor: 3.857

Review 7.  Progress in type II dehydroquinase inhibitors: from concept to practice.

Authors:  Concepción González-Bello; Luis Castedo
Journal:  Med Res Rev       Date:  2007-03       Impact factor: 12.944

Review 8.  Drug discovery in tuberculosis. New drug targets and antimycobacterial agents.

Authors:  André Campaniço; Rui Moreira; Francisca Lopes
Journal:  Eur J Med Chem       Date:  2018-03-09       Impact factor: 6.514

9.  Identification of compounds with potential antibacterial activity against Mycobacterium through structure-based drug screening.

Authors:  Tomohiro Kinjo; Yuji Koseki; Maiko Kobayashi; Atsumi Yamada; Koji Morita; Kento Yamaguchi; Ryoya Tsurusawa; Gulcin Gulten; Hideyuki Komatsu; Hiroshi Sakamoto; James C Sacchettini; Mitsuru Kitamura; Shunsuke Aoki
Journal:  J Chem Inf Model       Date:  2013-04-19       Impact factor: 4.956

10.  Looking back to the future: predicting in vivo efficacy of small molecules versus Mycobacterium tuberculosis.

Authors:  Sean Ekins; Richard Pottorf; Robert C Reynolds; Antony J Williams; Alex M Clark; Joel S Freundlich
Journal:  J Chem Inf Model       Date:  2014-04-03       Impact factor: 4.956

View more
  1 in total

1.  SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19.

Authors:  Ilaria Vicenti; Maurizio Zazzi; Francesco Saladini
Journal:  Expert Opin Ther Pat       Date:  2021-03-03       Impact factor: 6.674

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.